Limiting glioma development by photodynamic therapy-generated macrophage vaccine and allo-stimulation: an in vivo histological study in rats

• Published in: Journal of biomedical optics Vol. 23; no. 2; p. 028001
• Main Authors: Madsen, Steen J, Christie, Catherine, Huynh, Khoi, Peng, Qian, Uzal, Francisco A, Krasieva, Tatiana B, Hirschberg, Henry
• Format: Journal Article
• Language: English
• Published: United States Society of Photo-Optical Instrumentation Engineers 01.02.2018
• Subjects: Research Papers: Therapeutic; glioma; immunogenic apoptotic cells; macrophages; allogeneic cells; photodynamic therapy; photodynamic therapy-macrophage vaccine
• ISSN: 1083-3668; 1560-2281
• DOI: 10.1117/1.JBO.23.2.028001

Immunotherapy of brain tumors involves the stimulation of an antitumor immune response. This type of therapy can be targeted specifically to tumor cells thus sparing surrounding normal brain. Due to the presence of the blood-brain barrier, the brain is relatively isolated from the systemic circulation and, as such, the initiation of significant immune responses is more limited than other types of cancers. The purpose of this study was to show that the efficacy of tumor primed antigen presenting macrophage (MaF98) vaccines can be increased by: (1) photodynamic therapy (PDT) of the priming tumor cells and (2) intracranial injection of allogeneic glioma cells directly into the tumor site. Experiments were conducted in an in vivo brain tumor development model using Fischer rats and F98 (syngeneic) and BT4C (allogeneic) glioma cells. The results showed that immunization with Ma (acting as antigen-presenting cells), primed with PDT-treated tumor cells (MaF98), significantly slowed but did not prevent the growth of F98-induced tumors in the brain. Complete suppression of tumor development was obtained via MaF98 inoculation combined with direct intracranial injection of allogeneic glioma cells. No deleterious effects were noted in any of the animals during the 14-day observation period.